We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Testosterone (TRT) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Tamoxifen (Nolvadex) and Testosterone (TRT) have evidence — compare verdict strength side-by-side.
Approved (oncology) / off-label (male) — clinician-directed. For ER-positive breast cancer the standard adjuvant dose is 20 mg once daily for 5-10 years. For off-label male gynecomastia, the randomized trials used roughly 10-20 mg daily (10 mg/day prophylactically alongside an antiandrogen, 20 mg/day to treat established gynecomastia). For idiopathic male infertility, the trials typically used 20 mg/day. Bodybuilding 'post-cycle therapy' commonly uses 10-40 mg/day tapered — a use with no controlled-trial evidence. There is no FDA-approved male dose.
any
Tamoxifen citrate tablets (approved for breast cancer; off-label in men)
Prescription-only and clinician-directed — this is a controlled substance, NOT a self-administered supplement, and we do not provide a non-medical dosing protocol. For context only: TRT for diagnosed hypogonadism is titrated to a mid-normal testosterone level. Intramuscular testosterone esters (cypionate/enanthate) are commonly dosed around 50–100 mg weekly (or ~100–200 mg every 2 weeks); long-acting testosterone undecanoate is dosed less frequently. Transdermal gels (~50–100 mg/day applied) and subcutaneous injection are alternative routes. Supraphysiologic anabolic-steroid doses are far higher, illegal, and dangerous — not a regimen this library endorses.
any
Clinician-prescribed testosterone (intramuscular ester or transdermal gel) for diagnosed hypogonadism — controlled substance, prescription-only
Years
Weeks to months
Weeks to a few months
Throughout use
Weeks to months
Months
Months
Throughout use
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Lancet (2011) · Meta analysis
EBCTCG patient-level meta-analysis of randomized adjuvant-tamoxifen trials; ER-positive disease cohort n=10,645
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
J Natl Cancer Inst (1998) · Rct · n=13388
NSABP P-1: randomized, placebo-controlled prevention trial of 20 mg/day tamoxifen for 5 years in 13,388 women at increased breast-cancer risk
A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.
Clin Genitourin Cancer (2012) · Rct · n=176
Randomized multicenter trial in 176 men on bicalutamide monotherapy for prostate cancer: reactive tamoxifen 20 mg/day (arm A) vs prophylactic tamoxifen 10 mg/day started with bicalutamide (arm B)
Effects of Testosterone Treatment in Older Men.
The New England journal of medicine (2016) · Rct · n=790
The coordinated Testosterone Trials (TTrials) — seven randomized, double-blind, placebo-controlled trials in 790 men aged 65+ with confirmed low testosterone and symptoms, treated with testosterone gel for one year
Cardiovascular Safety of Testosterone-Replacement Therapy.
The New England journal of medicine (2023) · Rct · n=5246
TRAVERSE: a randomized, double-blind, placebo-controlled non-inferiority trial of transdermal testosterone in 5246 middle-aged and older hypogonadal men with high cardiovascular risk — the largest TRT cardiovascular-safety trial
Safety and Efficacy of Testosterone Therapy on Musculoskeletal Health and Clinical Outcomes in Men: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
Endocrine practice (2023) · Meta analysis
Systematic review and meta-analysis of 16 randomized placebo-controlled trials (1728 men, mean age 77) of testosterone therapy on musculoskeletal outcomes
Testosterone (TRT) has a higher evidence score (5.6/10 vs 5.2/10) and wins in 2 of 3 categories.
No known interactions between Tamoxifen (Nolvadex) and Testosterone (TRT) have been documented in our database. However, always consult a healthcare provider before combining supplements.